CPC technology class · C07
C07J - Steroids
Steroids. 1,454 US utility patents granted 2015–2025, with the leading assignees and year-by-year grant trajectory.
- 1,454
- US patents granted
- #7/8
- in C07
- 0.8%
- C07 class share
- -21%
- 5-yr velocity
The verdict
According to USPTO PatentsView, Steroids ranks #408 of 670 CPC technology areas - 1,454 US patents granted since 2015, with recorded grant volume down 21% over five years.
- #408
- of 670 CPC technology areas
- 1,454
- US patents granted, 2015–2025
- Sage Therapeutics
- leading assignee (85)
- -21%
- grant velocity, last 5 yrs
How C07J's grant cadence moved
Between 2020–2024, C07J recorded 547 grants versus 694 in 2015–2019 (-21% equal-window velocity). Across complete years, output peaked in 2019 at 164 grants and bottomed in 2024 at 83 (+98% peak-over-trough). Lead assignee Sage Therapeutics, Inc. holds 5.8% of the class ; the top three share 10.6%.
Leaderboard read
C07J concentration, lead at 5.8%
Sage Therapeutics, Inc. leads this historical grant record at 5.8% of C07J - us corporation assignees hold 59% of class grants (458 of 782). Figures describe granted US utility patents in this CPC subclass, not current investment or legal strength.
- Leader's share
- 5.8%
- Top three share
- 10.6%
- Lead over #2
- 46
85 of 1,454 grants
of the class's recorded grants
more grants than Intercept Pharmaceuticals, Inc.
Where C07J sits inside C07
Among 8 subclasses in C07 (Organic Chemistry), C07J ranks #7 and holds 0.8% of the parent class's 176,064 recorded grants. Sibling chips below are the other subclasses in the same parent class, not the nationwide volume/lead-share peers further down.
Rising assignees active in C07J
Company-wide grant multiples (2022–2024 vs 2019–2021) among assignees with ≥5 patents in this subclass. Growth is company-wide; class patent counts are subclass-specific.
- #1 Nammi Therapeutics, Inc. 7.00x 0 → 7 company-wide · 7 in C07J
- #2 Aposense Ltd 3.00x 1 → 3 company-wide · 7 in C07J
- #3 Beijing Peking University WBL Biotech Co., Ltd. 3.00x 1 → 3 company-wide · 6 in C07J
- #4 Industriale Chimica S.R.L. 1.50x 2 → 3 company-wide · 12 in C07J
- #5 Guangzhou Cellprotek Pharmaceutical Co., Ltd 1.50x 2 → 3 company-wide · 5 in C07J
C07J grants by year, peak 2019 (164)
US utility-patent grants per year in C07J, 2015–2025 - recent five years are down 21% versus 2015–2019.
Who leads C07J?
The 12 most active assignees in Steroids - wider bars mean more grants
- Sage Therapeutics
Sage Therapeutics, Inc.
85 patents
- Intercept Pharmaceutic…
Intercept Pharmaceuticals, Inc.
39 patents
- Reata Pharmaceuticals… 30
Reata Pharmaceuticals Holdings, LLC
30 patents
- Enanta Pharmaceuticals 20
Enanta Pharmaceuticals, Inc.
20 patents
- Pop Test Oncology 18
Pop Test Oncology LLC
18 patents
- Brigham Young… 16
Brigham Young University
16 patents
- Bayer Intellectual… 12
Bayer Intellectual Property GmbH
12 patents
- Arcturus Therapeutics 12
Arcturus Therapeutics, Inc.
12 patents
- Kythera Biopharmaceuti… 12
Kythera Biopharmaceuticals, Inc.
12 patents
- Industriale Chimica S… 12
Industriale Chimica S.R.L.
12 patents
- Dana-farber Cancer… 11
Dana-farber Cancer Institute, Inc.
11 patents
- Infinity Pharmaceutica… 11
Infinity Pharmaceuticals, Inc.
11 patents
What this shows Sage Therapeutics is the most active filer in C07J, holding 85 of the 1,454 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.
View data table
| Rank | Company | Patents in C07J |
|---|---|---|
| #1 | Sage Therapeutics, Inc. | 85 |
| #2 | Intercept Pharmaceuticals, Inc. | 39 |
| #3 | Reata Pharmaceuticals Holdings, LLC | 30 |
| #4 | Enanta Pharmaceuticals, Inc. | 20 |
| #5 | Pop Test Oncology LLC | 18 |
| #6 | Brigham Young University | 16 |
| #7 | Bayer Intellectual Property GmbH | 12 |
| #8 | Arcturus Therapeutics, Inc. | 12 |
| #9 | Kythera Biopharmaceuticals, Inc. | 12 |
| #10 | Industriale Chimica S.R.L. | 12 |
| #11 | Dana-farber Cancer Institute, Inc. | 11 |
| #12 | Infinity Pharmaceuticals, Inc. | 11 |
| #13 | ViiV Healthcare UK (No.5) Limited | 11 |
| #14 | Cassiopea S.P.A. | 10 |
| #15 | NeurMedix, Inc. | 9 |
| #16 | Virginia Commonwealth University | 8 |
| #17 | Neupharma, Inc | 8 |
| #18 | Allergan Sales, LLC | 8 |
| #19 | ReveraGen BioPharma, Inc. | 8 |
| #20 | NZP UK Limited | 8 |
Footprint here vs. claim strategy
Each dot is a leading C07J assignee, placed by how many patents it holds in this class (horizontal) against its company-wide average claims per patent (vertical) - a read on whether the class is led by broad-but-shallow filers or focused deep-claim players.
Classes near C07J's 1,454-grant footprint
Nationwide nearest neighbors for C07J (#408 of 670 by volume ; lead share 5.8%) - not the C07 parent-class siblings above.
Nearest by grant volume
Questions about C07J
Which company holds the most patents in C07J?
Which C07J assignees grew fastest recently?
How does C07J compare inside parent class C07?
What to do with this data
C07J in context - here's where to go next.
- Sage Therapeutics, Inc. leads C07J with 85 grants in this class. See full portfolio
- C07J ranks #408 of 670 by grant volume among all tracked CPC technology areas. See the ranking
- Inside parent class C07, the largest sibling subclass is C07K with 58,046 grants. Explore C07K
Figures reflect USPTO PatentsView grant data through 2026-05-15; pending applications not yet granted are not counted.
Methodology - C07J figures are USPTO PatentsView granted-utility totals for this subclass (1,454 grants in the tracked window).
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.